Recent Updates
Recently added Catalysts

Diphteria, tetanus, and Acellular Pertussis vaccine

Phase 3

Diphtheria | Monoclonal antibody | Infectious Disease |Sanofi|Last Updated: Apr 14, 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials2
Total Enrollment341

FDA Designations

No designations recorded

Clinical trial landscape

Diphteria, tetanus, and Acellular Pertussis vaccine · 2 trials · 5 indications

Phase 3 2
NCT00259337Immunogenicity and Safety of Pentaxim™ in an Indian PopulationDiphtheria
COMPLETED226 Analytics
NCT00258908Immunogenicity and Safety of ADACEL™ as Fifth Dose in TaiwanDiphtheria
COMPLETED115 Analytics
PHASE3COMPLETED
Immunogenicity and Safety of Pentaxim™ in an Indian Population
DiphtheriaUnlock trial analytics
PHASE3COMPLETED
Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan
DiphtheriaUnlock trial analytics

Study Endpoints

Primary Endpoints

To provide information concerning the safety of DTacP-IPV//PRP~T combined vaccine
19 months
Percentage of Participants With Antibody (Anti-diphtheria, Anti-tetanus, and Anti-pertussis Toxoids) Responses Pre- and Post-vaccination
Day 0 and Day 28 Post-vaccination

Immunogenicity profile of ADACEL™ (TdcP vaccine) antibody (anti-diphtheria, anti-tetanus, and anti-pertussis) responses at Day 0 and Day 28 Post-vaccination.

Geometric Mean Titers (GMTs) of Anti-diphtheria, Anti-tetanus, and Anti-pertussis Toxoids Pre- and Post-vaccination
Day 0 and Day 28 post-vaccination

GMTs and 95% confidence intervals of anti-diphtheria, anti-tetanus, and anti-pertussis toxoids responses at Day 0 and Day 28 Post-vaccination.

Secondary Endpoints

Percentage of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination
Within 8 days of vaccination
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposePREVENTION

Treatment Arms

ArmTypeDescription
1EXPERIMENTAL -

Interventions

NameTypeDescription
Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccineBIOLOGICAL0.5 mL, IM
Diphteria, tetanus, and Acellular Pertussis vaccineBIOLOGICAL0.5 mL, Intramuscular
Unlock Study Design Details

Eligibility Criteria

Age Range42 Days to 56 Days
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Aged 42 to 56 days inclusive on the day of inclusion * Born at full term pregnancy (\> 37 weeks) with a birth weight ≥ 2.5 kg * Informed consent form signed by the parent(s) or other legal representative * Able to attend all scheduled visits and to comply with all trial proced...

Countries:IndiaTaiwan
Unlock Eligibility Criteria